Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: Review and recommendations from the Parent Project Muscular Dystrophy expert panel

Christopher F. Spurney*, Deborah Ascheim, Lawrence Charnas, Linda Cripe, Kan Hor, Nicholas King, Kathi Kinnett, Elizabeth M. McNally, John Michael Sauer, Lee Sweeney, Chet Villa, Larry W. Markham

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Cardiac disease is now the leading cause of death in Duchenne muscular dystrophy (DMD). Clinical evaluations over time have demonstrated asymptomatic cardiac troponin elevations and acute elevations are associated with symptoms and cardiac dysfunction in DMD. Clinicians require a better understanding of the relationship of symptoms, troponin levels and progression of cardiac disease in DMD. As clinical trials begin to assess novel cardiac therapeutics in DMD, troponin levels in DMD are important for safety monitoring and outcome measures. The Parent Project Muscular Dystrophy convened an expert panel of cardiologists, scientists, and regulatory and industry specialists on 16 December 2019 in Silver Spring, Maryland and reviewed published and unpublished data from their institutions. The panel recommended retrospective troponin data analyses, prospective longitudinal troponin collection using high-sensitivity cardiac troponin I assays, inclusion of troponin in future clinical trial outcomes and future development of clinical guidelines for monitoring and treating troponin elevations in DMD.

Original languageEnglish (US)
Article numbere001592
JournalOpen Heart
Volume8
Issue number1
DOIs
StatePublished - Mar 24 2021
Externally publishedYes

Keywords

  • biomarkers
  • cardiomyopathy
  • dilated
  • genetic diseases
  • inborn

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: Review and recommendations from the Parent Project Muscular Dystrophy expert panel'. Together they form a unique fingerprint.

Cite this